Guggenheim raised the firm’s price target on BrightSpring Health to $18 from $15 and keeps a Buy rating on the shares. The firm raised estimates in FY24 and FY25 “across the board” on the strength of continued outperformance in both the pharmacy and provider operating segments, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- Dr. Steve Miller Joins BrightSpring Health’s Expanded Board
- BrightSpring Health appoints Steve Miller to board of directors
- Walgreens liquidity concerns to persist, says Barclays
- KKR to purchase 11.62M shares of BrightSpring Health from Walgreens
- North Central Florida Hospice completes asset sale to BrightSpring Health